missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CDIP1 Polyclonal Antibody, Invitrogen™
Rabbit Polyclonal Antibody
Brand: Invitrogen PA520697
This item is not returnable.
View return policy
Description
A suggested positive control is human brain tissue lysate. PA5-20697 can be used with blocking peptide PEP-0812.
The p53 tumor-suppressor gene integrates numerous signals that control cell life and death; loss of its functions contributes to the development of most cancers. CDIP is a novel pro-apoptotic target gene whose inhibition abrogates p53-mediated apoptotic responses. Overexpression of CDIP induced apoptosis in transfected cells while siRNA suppression of caspase-8 mRNA blocked this CDIP-induced apoptosis, indicating that the CDIP-dependent apoptosis pathway proceeds through extrinsic cell death pathway. CDIP may thus represent a novel target for drug design to maximize p53 response and sensitize tumor cells to cancer therapy. Multiple isoforms of CDIP are known to exist.
Specifications
CDIP1 | |
Polyclonal | |
Unconjugated | |
CDIP1 | |
2700048O17Rik; 5730403B10Rik; AU018521; AW742692; C16orf5; CDIP; CDIP1; cell death inducing protein; cell death inducing Trp53 target 1; cell death involved p53-target; cell death-inducing p53 target 1; cell death-inducing p53-target protein 1; Cell death-inducing protein; I1; Lipopolysaccharide-induced tumor necrosis factor-alpha-like protein; LITAFL; LITAF-like protein; Transmembrane protein I1 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
29965, 66626 | |
Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C | |
Liquid |
Immunohistochemistry, Western Blot | |
1 mg/mL | |
PBS with 0.02% sodium azide | |
Q9DB75, Q9H305 | |
CDIP1 | |
A 19 amino acid peptide near the center of human CDIP. | |
100 μg | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction